News archives


JANUARY - MARCH 18

OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  9th March  
  A*STAR ETPL Awards $ 3-Million Grant to Dr. Zeng Qi's team
 
 



Investigator: Dr Zeng Qi
Co-Investigators: Prof Neal Copeland, Prof Nancy Jenkins, Prof Jean Paul Thirery, Prof Wanjin Hong and Prof Philip Ingham.


IMCB Executive Director Professor Neal Copeland and lead scientist Dr. Zeng Qi have received a $ 3.1 million Flagship grant award from Mr. Boon Swan Foo, Executive Chairman of ETPL (Exploit Technologies Pte Ltd -A member of A*STAR). Deputy Directors Professors Nancy Jenkins Copeland, Wanjin Hong, and Philip Ingham also attended the award ceremony held at ETPL’s boardroom on February 27, 2009.

The prestigious award aims to support Dr. Zeng’s research team to explore a unique approach of inhibiting human cancer metastases using antibodies against PRL-3 phosphatase. ETPL expects her team to generate several humanized PRLs’ antibodies as candidates for therapeutic agents to treat multiple human cancers associated with overexpression of PRL-phosphatases, as several pharmaceutical and biotech companies have expressed strong interests in the proposed antibody therapies in mice.

Mr. Boon congratulates IMCB for the first such Flagship award and hopes to see more Flagship grants awarded to IMCB in the future. Professor Copeland and the Deputy Directors congratulate Dr. Zeng and her team for their impressive progress that anchored the award to IMCB.

Dr. Zeng Qi’s website: http://www.imcb.a-star.edu.sg/php/qz.php